FDA Recent Advisories: Monitoring is Issue
The Food and Drug Administration (FDA) recently put out two important advisories:
Families, patients, and clinicians of all ages should more closely monitor the effects of antidepressants in the treatment of depression (March, 2004).
There is an increased risk (4% compared to 2%) of suicidal thinking and behavior in children and adolescents on antidepressants (October, 2004).
Families for Depression Awareness believes that monitoring is the key issue.